Expert Interviews

Mark Pegram, MD, spoke about using the Breast Cancer Index and Clinical Treatment Score post-5 years to determine outcomes for patients with early-stage hormone receptor–positive breast cancer treated with adjuvant endocrine therapy.

Amrita Y. Krishnan, MD, spoke about where future research in multiple myeloma is headed and a take-home message for her colleagues about teclistamab in heavily pretreated patients.

Aaron Gerds, MD, explains the various types of myelofibrosis and the underlying pathophysiologies.

Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification.

Benjamin Cooper, MD, discussed an ongoing trial examining TAK-676 in combination with pembrolizumab after radiation therapy for patients with non–small cell lung cancer, head and neck cancer, and triple-negative breast cancer.

Roger Li, MD, spoke about responses from the CORE1 trial that examined patients with non–muscle invasive bladder cancer treated with CG0070 plus pembrolizumab.

C. Ola Landgren, MD, PhD, highlights the rationale for the phase 3 DETERMINATION trial, assessing the use of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Steven J. Chmura, MD, PhD, spoke about interesting findings from a phase 2R/3 trial of patients with newly oligometastatic breast cancer who were given standard of care systemic treatment with or without stereotactic body radiotherapy and/or surgical resection.

Roger Li, MD, spoke about the mechanism of action of CG0070 used in combination with pembrolizumab to treat patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.

Dr Fonseca discusses approaches for treating frail patients with multiple myeloma and those with high-risk disease.

Before closing their discussion on transplant-eligible, newly diagnosed multiple myeloma, experts consider duration of therapy in this setting.

Panelists briefly review factors they use to select induction therapy for patients with transplant-eligible, newly diagnosed multiple myeloma.

Xiuning Le, MD, PhD, spoke about the use of ctDNA biomarkers and why research should continue for those with advanced non–small cell lung cancer with high MET-amplification being treated with tepotinib.

Xiuning Le, MD, PhD, spoke about unmet needs in patients with advanced non–small cell lung cancer with high MET-amplifications and why tepotinib may be a good treatment option.

Karen L. Reckamp, MD, spoke about safety signals that emerged in the Lung-MAP nonmatched phase 2 substudy S1800A and what the next steps are for the combination of ramucirumab/pembrolizumab in patients with non–small cell lung cancer pretreated with chemotherapy and immunotherapy

Shubham Pant, MD, highlights the importance of tailoring treatment in patients with pancreatic cancer by exploring biomarkers.

Biagio Ricciuti, MD, spoke about the 3-year follow-up and prolonged survival benefit in patients with non–small cell lung cancer who had very high PD-L1 expression of 90% or more.

Richard Kim, MD, highlights future research efforts examining immunotherapy/chemotherapy combinations for patients with metastatic colorectal cancer.

Karen L. Reckamp, MD, spoke about the rationale behind the Lung-MAP S1800A substudy of pembrolizumab plus ramucirumab for patients with non–small cell lung cancer and the topline results from 2022 ASCO.

Rafael Fonseca, MD reviews the MAIA clinical trial and strategies for choosing the appropriate patients with transplant-ineligible newly diagnosed MM.